Lucid Diagnostics Files 8-K

TL;DR

Lucid Diagnostics filed an 8-K on 5/24/24. Standard corporate update.

AI Summary

Lucid Diagnostics Inc. filed an 8-K on May 24, 2024, reporting other events and financial statements/exhibits. The company, incorporated in Delaware with its principal executive offices in New York, is involved in the surgical and medical instruments and apparatus industry.

Why It Matters

This filing indicates Lucid Diagnostics is providing updates on its corporate activities and financial status to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — This is a routine filing reporting corporate events and financial information, not indicating any immediate significant risk.

Key Numbers

• 001-40901 — SEC File Number (Identifies the company's filing with the SEC.)
• 82-5488042 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Lucid Diagnostics Inc. (company) — Registrant
• May 24, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• New York (location) — Address of Principal Executive Offices
• 3841 (sic_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, Par Value $0.001 Per Share LUCD The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 40KB
• 0001493152-24-021374.txt ( ) — 211KB
• lucd-20240524.xsd (EX-101.SCH) — 3KB
• lucd-20240524_lab.xml (EX-101.LAB) — 33KB
• lucd-20240524_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2024 LUCID DIAGNOSTICS INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40901 82-5488042 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 360 Madison Avenue , 25 th Floor , New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (917) 813-1828 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.001 Per Share LUCD The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. The board of directors of Lucid Diagnostics Inc. (the " Company ") has determined to reschedule the Company's 2024 annual meeting of stockholders (the " Annual Meeting "). The Annual Meeting, previously scheduled for 11:00 a.m. Eastern Time on June 20, 2024, has been rescheduled for 11:00 a.m. Eastern Time on July 23, 2024. The Annual Meeting was rescheduled in order to modify the proposals to be voted upon. The Company established a new record date of May 29, 2024 for determining stockholders entitled to notice of and to vote at the rescheduled Annual Meeting. As a result, the Company will send a new notice and proxy statement for the rescheduled Annual Meeting. There is no change to the location of the Annual Meeting. Stockholders will be able to attend and participate in the rescheduled Annual Meeting online by visiting https://www.cstproxy.com/luciddx/2024 . Important Additional Information and Where to Find It Concurrently with the filing of this current report, the Company is filing a revised preliminary proxy statement on Schedule 14A with the Securities and Exchange Commission (the " SEC ") in connection with the rescheduled Annual Meeting. Following the filing of the revised definitive proxy statement with the SEC, the Company will mail the revised definitive proxy statement and a revised proxy card to each stockholder entitled to vote at the rescheduled Annual Meeting. Investors and security holders are encouraged to read the revised preliminary proxy statement, and the revised definitive proxy statement and any other relevant documents filed with the SEC when such documents become available, because they will contain important information. Security holders will be able to obtain the revised preliminary proxy statement, and when available the revised definitive proxy statement and other relevant materials filed by the Company with the SEC, free of charge at the SEC's website, www.sec.gov , or from the Company at its website, www.luciddx.com . Participants in Solicitation The Company and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies for the rescheduled Annual Meeting. Information concerning the Company's participants is set forth in the revised preliminary proxy statement, being filed concurrently with this current report, for the rescheduled Annual Meeting. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the rescheduled Annual Meeting may be included in the revised definitive proxy statement and other relevant materials to be filed with the SEC when they become available. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of t

View Full Filing

View this 8-K filing on SEC EDGAR